Technical Analysis for GTXI - GTx, Inc.

Grade Last Price % Change Price Change
grade D 1.3 -1.52% -0.02
GTXI closed down 1.52 percent on Tuesday, March 19, 2019, on 30 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Down Up Down
See historical GTXI trend table...

Date Alert Name Type % Chg
Mar 19 Doji - Bullish? Reversal 0.00%
Mar 19 Wide Bands Range Expansion 0.00%
Mar 18 Narrow Range Bar Range Contraction -1.52%
Mar 18 Wide Bands Range Expansion -1.52%
Mar 15 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Mar 15 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 15 Calm After Storm Range Contraction 0.00%
Mar 15 Wide Bands Range Expansion 0.00%
Mar 14 Boomer Buy Setup Bullish Swing Setup -6.47%
Mar 14 Calm After Storm Range Contraction -6.47%

Older signals for GTXI ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules for the treatment of cancer, cancer supportive care, and other serious medical conditions. It is involved in developing Enobosarm, an androgen receptor modulator, which is in Phase III clinical trials for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer in the United States, Europe, Russia, and South America. The company also develops Capesaris, an oral nonsteroidal estrogen receptor alpha agonist that is in Phase II clinical trial for secondary hormonal therapy in men with metastatic castration resistant prostate cancer. In addition, its preclinical development stage products include inhibitors of steroid biosynthetic enzymes, anticancer therapies, estrogen receptor beta agonists, and other novel compounds for the potential treatment of cancer, metabolic diseases, ophthalmic diseases, psoriasis, and pain. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.
Chemistry Biopharmaceutical Cancer Pain Alpha Treatment Of Cancer Endocrine System Non Small Cell Lung Cancer Organic Chemistry Psoriasis Alcohols Metabolic Diseases Hepatotoxins Metastatic Castration Resistant Prostate Cancer Androgen Receptor Anticancer Therapies Estrogens Intracellular Receptors Transcription Factors
Is GTXI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 25.6
52 Week Low 0.74
Average Volume 1,061,311
200-Day Moving Average 8.0606
50-Day Moving Average 1.0556
20-Day Moving Average 1.1894
10-Day Moving Average 1.3228
Average True Range 0.2041
ADX 50.81
+DI 43.9793
-DI 11.4919
Chandelier Exit (Long, 3 ATRs ) 1.9477
Chandelier Exit (Short, 3 ATRs ) 1.4523
Upper Bollinger Band 1.604
Lower Bollinger Band 0.7748
Percent B (%b) 0.63
BandWidth 69.715823
MACD Line 0.0887
MACD Signal Line 0.0752
MACD Histogram 0.0135
Fundamentals Value
Market Cap 20.88 Million
Num Shares 16.1 Million
EPS -1.71
Price-to-Earnings (P/E) Ratio -0.76
Price-to-Sales 0.00
Price-to-Book 14.80
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.47
Resistance 3 (R3) 1.47 1.42 1.44
Resistance 2 (R2) 1.42 1.38 1.42 1.43
Resistance 1 (R1) 1.36 1.35 1.34 1.36 1.42
Pivot Point 1.31 1.31 1.30 1.31 1.31
Support 1 (S1) 1.25 1.27 1.23 1.25 1.18
Support 2 (S2) 1.20 1.24 1.20 1.17
Support 3 (S3) 1.14 1.20 1.16
Support 4 (S4) 1.14